Using ultrasound to assess liver cancer treatment responses
Role of Dynamic Contrast-Enhanced Ultrasound (D-CEUS) and Shear-wave Elastography (SWE) in Predicting Response to Locoregional Treatments and Disease Recurrence in Patients Affected by Hepatocellular Carcinoma (HCC)
This study is testing if ultrasound scans can help predict how well liver cancer treatments work for patients with hepatocellular carcinoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma) |
| Trial ID | NCT05987514 on ClinicalTrials.gov |
What this trial studies
This study evaluates how pre-treatment ultrasound parameters can predict the response to locoregional treatments for hepatocellular carcinoma (HCC). It involves enrolling 50 patients who will undergo contrast-enhanced ultrasound (CEUS) and shear wave elastography (SWE) before and after their treatment. The primary goal is to correlate these ultrasound findings with the one-month response to therapy, while secondary objectives include identifying ultrasound parameters that may predict overall and disease-free survival. Patients will also be monitored through regular follow-ups including imaging studies.
Who should consider this trial
Good fit: Ideal candidates are adults with a single nodule of hepatocellular carcinoma who are scheduled for locoregional treatment.
Not a fit: Patients with liver failure, previous treatments for HCC, or those with certain heart conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the ability to predict treatment responses in patients with liver cancer, leading to better personalized treatment plans.
How similar studies have performed: While the approach of using ultrasound parameters for treatment response prediction is gaining interest, this specific study's methodology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria adult patients with single nodule hepatocellular carcinoma detectable with B-mode ultrasound and scheduled for locoregional treatment Exclusion Criteria: * liver failure * previous treatments fo hepatocellular carcinoma * chronic or acute heart failure * known ipersesitivity to ultrasound contrast agent * pregnancy and lactation
Where this trial is running
Roma
- Fondazione Policlinico Gemelli IRCCS — Roma, Italy (Recruiting)
Study contacts
- Study coordinator: Maria Assunta Zocco
- Email: mariaassunta.zocco@policlinicogemelli.it
- Phone: 00393470597805
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.